# Opioid Use Disorder: Endpoints for Demonstrating Effectiveness of Drugs for Treatment Guidance for Industry - FDA Guidance Document

Source: https://www.globalkeysolutions.net/guidances/guidance-document/opioid-use-disorder-endpoints-for-demonstrating-effectiveness-of-drugs-for-treatment-guidance-for-industry/88ee7ab4-2004-41c5-9b57-36cc6087d892

> FDA guidance document: Opioid Use Disorder: Endpoints for Demonstrating Effectiveness of Drugs for Treatment Guidance for Industry. Issue date: October 01, 2020. Get complete insights and analysis.

---

## Details

- Title: Opioid Use Disorder: Endpoints for Demonstrating Effectiveness of Drugs for Treatment Guidance for Industry
- Communication Type: Guidance Document
- Product Type: drugs
- Office Name: Center for Drug Evaluation and Research
- Office URL: /offices/center-for-drug-evaluation-and-research/cd980d74-1cbf-4226-ba9a-9045324c236c
- Issue Date: 2020-10-01
- Last Changed: 2020-10-05
- Docket Number: <a href="https://www.regulations.gov/docket/FDA-2018-D-2382">FDA-2018-D-2382</a>

## Related Documents

- [Acne Vulgaris:  Establishing Effectiveness of Drugs Intended for Treatment](https://www.globalkeysolutions.net/guidances/guidance-document/acne-vulgaris-establishing-effectiveness-of-drugs-intended-for-treatment/513aaac8-5cc8-4e47-8797-621cd7679a08)
- [Eosinophilic Esophagitis: Developing Drugs for Treatment Guidance for Industry](https://www.globalkeysolutions.net/guidances/guidance-document/eosinophilic-esophagitis-developing-drugs-for-treatment-guidance-for-industry/e454ac25-939f-4e9c-a8f1-b2613feff0b3)
- [Opioid Use Disorder: Developing Depot Buprenorphine Products for Treatment](https://www.globalkeysolutions.net/guidances/guidance-document/opioid-use-disorder-developing-depot-buprenorphine-products-for-treatment/f53ca142-5456-4eec-9cc0-358980e372cd)